Delivery Order 75N93021D00035-75N93026F00001
- Not listed
- This is a $5,758,524.34 delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to PPD Development LP, a global contract research organization (CRO). The contract is to provide monitoring services for a Phase III clinical trial, specifically trial A5300B/PHOENIX. It is a cost-plus-fixed-fee contract with an ultimate completion date of December 14, 2025. The contract was awarded on April 15, 2019 and is not...
- PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific, was awarded a delivery order valued at $2.79M by the National Institute of Allergy and Infectious Diseases (NIAID) on June 29, 2023. This task order falls under the Early Phase Clinical Trial Units (EPCTU) Indefinite Delivery/Indefinite Quantity (IDIQ) contract vehicle, which represents a $346M master agreement designed to support early-stage clinical research across multiple therapeutic...
- This is a federal contract award to PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services. The contract, valued at $139,861,060.22, is for NIAID Clinical Site Monitoring services. This is a definitive contract with a cost-plus-fixed-fee pricing type, with a period of performance through January 31, 2024. The...
- This is a $28,578,960 definitive, cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific. The contract is for clinical site monitoring services in support of NIAID's various clinical research programs, trials, and studies. It has a 10-year period of performance and was awarded on a full and open basis without a set-aside designation. The...
- This is a $75,173,993.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The contract provides comprehensive and rapid response services for NIAID's research programs related to HIV and other infectious diseases. This order falls under a larger $545 million Comprehensive and Rapid Response contract vehicle that...
- This is a $1,859,402 task order award under the National Institute of Allergy and Infectious Diseases' (NIAID) Early Phase Clinical Trial Units (EPCTU) indefinite delivery vehicle (IDV) contract. The prime contractor, PPD Development LP, is a global contract research organization that provides comprehensive clinical trial and research support services to federal agencies. This cost-plus-fixed-fee delivery order does not have a set-aside designation. PPD will perform the work in Cape Fear,...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $29.1M cost-plus-fixed-fee definitive contract to PPD Development LP on November 1, 2021, for regulatory management center services with an ultimate completion date of October 31, 2028. The contract, which carries no set-aside designation, supports NIAID's clinical research operations through the provision of regulatory management support services, including establishment and maintenance of electronic submission and...
- This is a $332,437,171.79 cost-plus-award-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to PPD Development LP, a global contract research organization, for clinical research support services related to HIV and other infectious diseases. The contract has an ultimate completion date of August 15, 2024 and was awarded on August 14, 2017. The original federal contract opportunity was a sources sought notice to discern if there were other contractors,...
- This is a $27,437,094.36 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to PPD Development LP, a global contract research organization (CRO) and subsidiary of Thermo Fisher Scientific. The contract is for research and development (R&D) in the biomedical (basic research) domain, specifically in support of NIAID's Regulatory Management Center. The contract does not have a set-aside designation and was awarded on a...
- This is a Cost Plus Fixed Fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to PPD Development LP, a global contract research organization and subsidiary of Thermo Fisher Scientific. The $18,792,842.54 contract is for the Immune Tolerance Network - Clinical Site Monitoring Group, which involves comprehensive clinical trial and research support services such as regulatory affairs, clinical site monitoring,...
- 75N93021D00035Indefinite Delivery Contract
- 75N93021D00035-75N93026F00001Delivery Order
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order valued at $21.6 million to PPD Development LP for Division of AIDS (DAIDS) monitoring services supporting the Phase III PHOENIX study (A5300B/I2003B). This contract, awarded December 15, 2025, with an ultimate completion date of December 14, 2028, will be performed in Cape Fear, North Carolina. The award utilizes a cost-plus-fixed-fee pricing structure with no set-aside designation and represents a child contract under a larger vehicle arrangement. PPD Development LP, a globally recognized contract research organization and subsidiary of Thermo Fisher Scientific, brings extensive experience in clinical trial management, regulatory support, and research coordination for federal medical research initiatives. The monitoring services provided under this delivery order support NIAID's critical infectious disease research portfolio. PPD Development LP holds significant federal contract vehicles with NIAID, including a $545 million Comprehensive and Rapid Response contract and a $346 million Early Phase Clinical Trial Units contract, demonstrating the company's established capabilities in clinical trial support and regulatory affairs. The firm's expertise encompasses clinical site monitoring, data management, protocol development, and specialized research support across therapeutic areas—capabilities essential for ensuring the safety, integrity, and regulatory compliance of Phase III clinical studies within the Division of AIDS research program.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1m | 12/10/25 |